REN and Hyperglycemia: 2019) and widely demonstrated to produce cardioprotective effects (Zhang Z et al. 2016). To further elucidate the modulation of tanshinone IIA on RAS cascade in bone tissue and the potential improvement on bone damages associated with hyperglycaemia, the STZ-injected diabetic mice were ip administered with tanshinone IIA for 8 weeks. The results suggested that tanshinone IIA was able to decrease in vivo circulating and skeletal ANG II level by potentially targeting renin.